Burn

Bispectral index for monitoring anesthetic depth in patients with severe burns receiving target-controlled infusion of remifentanil and propofol

Z. G. Guo, Jia, X. P., Wang, X. Y., Li, P., Su, X. J., and Hao, J. H., “Bispectral index for monitoring anesthetic depth in patients with severe burns receiving target-controlled infusion of remifentanil and propofol”, vol. 14, pp. 7597-7604, 2015.

This study evaluated the feasibility and effectiveness of using the bispectral index (BIS) to monitor anesthetic depth in patients with severe burns receiving intravenous target-controlled infusion (TCI) of remifentanil and propofol. We randomly assigned 80 patients undergoing elective escharectomy (<1 week) to BIS (A) and control (B) groups. All patients received remifentanil and propofol as intravenous TCI anesthesia. Clinical data were recorded at different time points.

Association between PAI-1 polymorphisms and plasma PAI-1 level with sepsis in severely burned patients

Y. F. Chi, Chai, J. K., Yu, Y. M., Luo, H. M., Zhang, Q. X., and Feng, R., “Association between PAI-1 polymorphisms and plasma PAI-1 level with sepsis in severely burned patients”, vol. 14, pp. 10081-10086, 2015.

We investigated the association between plasminogen activator inhibitor-1 (PAI-1) polymorphisms and plasma PAI-1 level with sepsis in severely burned patients. A total of 182 patients with burn areas lager than 30% of the body surface area were enrolled in this study. Peripheral blood samples were obtained from 103 patients with sepsis (sepsis group) and 79 patients without sepsis (control group). An allele-specific polymerase chain reaction assay was used to determine PAI-1 polymorphism 4G/5G distribution.

Subscribe to Burn